Author: admin
Funding accelerates clinical rollout of glycan biomarkers for aging and inflammation, pushing them into mainstream preventive care. GlycanAge, a London-based biotech pioneering glycan-based biomarkers for biological aging and chronic inflammation, has raised $8.7 million to accelerate clinical development and expand access to glycan testing in hospitals and preventive healthcare systems worldwide. The funding round was led by Fifth Quarter Ventures, with participation from Guinness Ventures, BrightCap Ventures, South Central Ventures, Impetus Capital, Vesna Deep Tech VC and Lightfield Equity. Existing investors, including LaunchHub Ventures and Kadmos Capital, also joined the round on a pro rata basis. The raise marks a…
Galux, a South Korean biotech doing research on AI-driven protein therapeutics discovery, entered into a research agreement with Boehringer Ingelheim to jointly explore the application of artificial intelligence (AI) in precision protein design for therapeutic development. The goal is to evaluate how AI can be leveraged to design purpose-specific protein molecules that meet precise scientific and translational needs, where conventional approaches face limitations. “Through this agreement, we aim to explore how AI protein design can address highly specific scientific and translational needs. These are challenges that often require precise and tailored molecular solutions,” said Chaok Seok, CEO of Galux. “It’s…
Credit: wildpixel/Getty Images Researchers at the Translational Genomics Research Institute (TGen) have identified distinct protein signatures carried by extracellular vesicles (EVs) in the blood of postmenopausal women that are associated with liver fat and development of metabolic dysfunction-associated steatotic liver disease (MASLD). Their research, published in BMC Medicine, showed that the EV protein INHBE consistently correlated with hepatic steatosis indicating that EVs may reflect biological pathways involved in MASLD development and progression. “With women specifically, we’re seeing an increase in hepatic steatosis with menopause. Estrogen provides some protection against metabolic disease, including diabetes and heart disease, but when women lose…
FDA clears ENV-308 for Phase 1 as Enveda doses first patient and appoints former Novo Nordisk executive to lead metabolic strategy. Clinical stage company Enveda has reached a pivotal point in its metabolic disease program, announcing US Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for ENV-308, alongside the dosing of the first patient in a Phase 1 clinical trial. The Boulder, Colorado-based clinical-stage biotech is also strengthening its leadership bench with the appointment of former Novo Nordisk Co-Founder and Head of the Transformational Prevention Unit, Nadeem Sarwar, PhD, MPharm, MPhil, as Senior Vice President…
JAX and NYSCF leaders, public officials, and supporters at the JAX-NYSCF ribbon tying event on Dec. 17. [The Jackson Laboratory] The Jackson Laboratory (JAX) and the New York Stem Cell Foundation (NYSCF) celebrated the official launch of their unified organization with a ribbon-tying ceremony at NYSCF’s Manhattan research facilities this week. The event brought together nearly 170 leading researchers, industry executives, local government officials, board members, staff, and supporters. “This is about building a new kind of research engine,” said Lon Cardon, PhD, JAX president and CEO, at the event. “When you bring together JAX’s leadership in mouse and cell…
Credit: designer491/Getty Images Sampling biases driven by the structure of bacterial populations dramatically affect the ability of machine learning (ML) to predict anti-microbial resistance (AMR), researchers have warned. The findings, in PLOS Biology, stress the importance of methods that take this population structure into account and use more diverse datasets to improve AMR prediction and surveillance. “Addressing the interplay between population structure and AMR prediction will require a multifaceted approach that includes improved sampling, algorithmic innovation, and systematic evaluation of proposed prediction methods,” the researchers, led by Yanying Yu, PhD, from Harvard Medical School, recommend. “Only by confronting these challenges…
Regenerative medicine firm says new capital gives it breathing room to sharpen its placenta-derived tech aimed at aging and chronic disease. Celularity Inc, a regenerative medicine company working at the intersection of biotechnology and aging science, has secured up to $12 million in new financing as it looks to steady its footing and refocus its long-term strategy. The funding comes at a challenging time for the company. Celularity’s shares have fallen sharply over the past year, and its market value has shrunk to under $40 million. Like many early-stage biotech firms, it has been balancing ambitious scientific goals with mounting…
An illustration of a self-assembling protein nanoparticle (SApNP) displaying Ebola virus surface proteins. This vaccine strategy is designed to help the immune system more effectively and respond to viral threats. [Scripps Research] Filoviruses, such as Ebola virus and Marburg virus, can cause viral hemorrhagic fever, with fatality rates reaching up to 90%. While two vaccines are approved for Ebola, no vaccine provides broad protection across the full filovirus family. The instability of filovirus surface proteins offers a challenge for immune system detection. In a new study published in Nature Communications titled, “Rational design of next-generation filovirus vaccines combining glycoprotein stabilization and nanoparticle display…
Organoids are self-assembling 3D cell culture models that mimic the structure and function of a desired organ, stemming from specific developmental layers. Organoid culture, therefore, provides a tool for studying organ development, disease modeling, and personalized medicine. These cultures require soluble factors to direct their proliferation, differentiation, and self-organization with the goal of creating organoids with improved functionality that are more reflective of in vivo conditions. Download this infographic to learn more about the origins of different organoid types and the cytokines, growth factors, and other reagents that researchers use to create specific organoid models.
Sponsored by: This podcast features Dr. Emma Luckett, whose work at Amsterdam UMC explores how genetics, DNA methylation, and amyloid PET imaging can together reveal the earliest biological signals of Alzheimer’s disease. She discusses the AMYPAD consortium’s large preclinical cohort, her efforts to model amyloid risk using multimodal data and machine learning, and the promise of blood‑based epigenetic markers for improving early detection, trial stratification, and future therapeutic targeting. This podcast is the third in a series. Read the first Methylation Matters: A New Era in Cardiovascular Risk Prediction with Dr. Charlotte Ling and the second Transforming Breast Cancer…